ONS Chemotherapy Immunotherapy Certificate Practice Test

Aprepitant is recognized as a common neurokinin-1 (NK1) antagonist used in the management of chemotherapy-induced nausea and vomiting (CINV). NK1 antagonists work by blocking the action of substance P, a neurokinin that plays a significant role in the vomiting reflex, particularly in the context of chemotherapy. Aprepitant is often used in combination with other antiemetic medications to enhance efficacy, especially in patients receiving highly emetogenic chemotherapy regimens.

Other agents listed, such as granisetron and ondansetron, are serotonin (5-HT3) antagonists, which block the serotonergic pathways involved in CINV, while dexamethasone is a corticosteroid that helps to reduce inflammation and is also used as an antiemetic in combination regimens. Each of these medications has a distinct mechanism of action, making aprepitant the specific choice for NK1 antagonism in the context of CINV management.